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Functional Analysis of the Neurofibromatosis Type 2 Protein
by Means of Disease-Causing Point Mutations
Renee P. Stokowski and David R. Cox
Department of Genetics, Stanford University, Stanford
Despite intense study of the neurofibromatosis type 2 (NF2) tumor-suppressor protein merlin, the biological prop-
erties and tumor-suppressor functions of merlin are still largely unknown. In this study, we examined the molecular
activities of NF2-causing mutant merlin proteins in transfected mammalian cells, to elucidate the merlin properties
that are critical for tumor-suppressor function. Most important, we found that 80% of the merlin mutants studied
significantly altered cell adhesion, causing cells to detach from the substratum. This finding implies a function for
merlin in regulating cell-matrix attachment, and changes in cell adhesion caused by mutant protein expression may
be an initial step in the pathogenesis of NF2. In addition, five different mutations in merlin caused a significant
increase in detergent solubility of merlin compared to wild type, indicating a decreased ability to interact with the
cytoskeleton. Although not correlated to the cell-adhesion phenotype, four missense mutations decreased the binding
of merlin to the ERM-interacting protein EBP-50, implicating this interaction in merlin inhibition of cell growth.
Last, we found that some NF2 point mutations in merlin most closely resembled gain-of-function alleles in their
cellular phenotype, which suggests that mutant NF2 alleles may not always act in a loss-of-function manner, as
had been assumed, but may include a spectrum of allelic types with different phenotypic effects on the function of
the protein. In aggregate, these cellular phenotypes provide a useful assay for identifying the functional domains
and molecular partners necessary for merlin tumor-suppressor activity.
Introduction
Neurofibromatosis type 2 (NF2) (MIM 101000) is an
autosomal disorder characterized by the formation of
nervous system tumors—specifically, bilateral schwan-
nomas of the eighth cranial nerve and, to a lesser extent,
schwannomas of other cranial and peripheral nerves and
spinal nerve roots, meningiomas, ependymonas, and
gliomas, as well as posterior lens-capsule opacities and
retinal abnormalities (Martuza and Eldridge 1988; Kai-
ser-Kupfer et al. 1989; Evans et al. 1992). Mutational
analysis of the NF2 gene in inherited and sporadic
schwannomas, meningiomas, and ependymonas has
shown that both copies of NF2 are often mutated and/
or deleted in 150% of tumors, which suggests that the
NF2 protein has a tumor-suppressor activity (Rouleau
et al. 1993; Trofatter et al. 1993; Bourn et al. 1994;
Jacoby et al. 1994; MacCollin et al. 1994). In support
of the NF2 protein’s proposed role as negative regulator
of cell growth, overexpression of the wild-typeNF2 gene
inhibits cell growth both in vitro and in vivo (Lutchman
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and Rouleau 1995; Sherman et al. 1997) and reverses
the Ras-induced phenotype of anchorage-independent
growth in v-Has-Ras transformed fibroblasts (Tikoo et
al. 1994).
The NF2 protein, nicknamed “merlin,” shares 45%
sequence identity with the family proteins ezrin, radixin,
and moesin (ERM) (MIM 309845), which link the actin
cytoskeleton to plasma membrane proteins at special-
ized, dynamic regions (Lamb et al. 1997; Martin et al.
1997). Like the ERM proteins, merlin localizes to the
plasma membrane at regions rich in filamentous actin,
both in cultured cells and endogenous tissues (den Bak-
ker et al. 1995a; Gonzalez-Agosti et al. 1996; Stemmer-
Rachamimov et al. 1997). Depletion of merlin protein
by antisense oligonucleotide treatment (Huynh and
Pulst 1996), as well as overexpression of merlin in cul-
tured cells, causes cellular changes associated with al-
terations in cell-matrix interactions, such as cell mor-
phology, cell motility, and cell-substrate attachment
(den Bakker et al. 1995b; Koga et al. 1998; Gutmann
et al. 1999). Furthermore, studies in cultured NIH3T3
cells demonstrate that endogenous levels of merlin ex-
pression and phosphorylation are responsive to changes
in cell adhesion, cell confluency, and growth factor stim-
uli (Shaw et al. 1998), which suggests that merlin may
function as part of a signal transduction pathway reg-
ulating cell-cell and cell-matrix interactions. Several
studies investigating merlin function have focused on
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identifying cellular interacting proteins.Merlin can bind
actin filaments in vitro (Xu and Gutmann 1998), and
immunoprecipitation studies have identified the actin-
binding protein bII-spectrin, the Na-H exchanger
regulatory cofactor EBP50, and the matrix receptor b1-
integrin as interactors of merlin (Murthy et al. 1998;
Obremski et al. 1998; Scoles et al. 1998). However, the
importance of these interactions to merlin tumor-sup-
pressor activity and NF2 pathogenesis has not been
clarified.
To elucidate the molecular mechanisms of NF2 tu-
mor-suppressor function, we analyzed the effect ofNF2
missense and deletion mutations on merlin cellular and
molecular properties in cultured mammalian cells, hy-
pothesizing that these changes would produce stable
proteins that are functionally defective. In this report,
we demonstrate that the majority of single amino acid
(aa) mutations in merlin produce proteins that signifi-
cantly inhibit cell adhesion and show increased deter-
gent solubility compared to wild-type merlin, which
suggests that merlin tumor-suppressor activity involves
cell-adhesion signaling. In addition, we provide evi-
dence that missense mutations can act as dominant al-
leles, which suggests the possibility that a subset ofNF2
mutant alleles in patients may act in a dominant manner
to promote tumorigenesis.
Material and Methods
Protein Expression Constructs
To create the untagged mammalian expression con-
structs, all cDNAs were cloned into the mammalian ex-
pression vector pcDNA3 (Invitrogen). The green fluo-
rescent protein (GFP) tag was fused N-terminal to all
cDNAs by means of the expression vector pEGFP-C1
(Clontech). All cDNAs were cloned into the pGEX-5X-
2 bacterial expression vector (Pharmacia Biotech), to
fuse glutathione-S-transferase (GST) to the amino ter-
minus of the protein of interest. The full-length merlin
cDNA clone for isoform 1 was isolated from a human
testes library in the vector pBK-CMV (Stratagene) and
was designated M7. All missense merlin constructs were
generated from the plasmid M7 by means of the oli-
gonucleotide-mediated mutagenesis protocol of Kunkel
et al. (1987), with primers engineered to contain the
exact nucleotide change reported in the literature as the
disease-associated mutation. The C-terminal coding se-
quence for isoform 2 was PCR amplified from human
lymphocyte cDNA and was subcloned into M7, to gen-
erate the full-length isoform 2 cDNA. For DCterm, a
unique internalXho1 site and theXho1 multiple cloning
site were used to “pop out” the carboxyl terminus of
M7, to produce a construct encoding aa 1–341 of mer-
lin. DNterm (aa 342–595) was generated by PCR am-
plification of the C-terminal half of merlin. Mer559 was
engineered by PCR amplification by means of internal
merlin primers. DBB was engineered essentially as de-
scribed elsewhere (LaJeunesse et al. 1998) for the Dro-
sophila “Blue Box” deletion. The entire EBP50 coding
sequence was isolated by HindIII/Not1 digestion, from
I.M.A.G.E. clone 33147 (Lennon et al. 1996). The full-
length human moesin cDNA was isolated by PCR from
I.M.A.G.E. clone 645267. The sequence of all constructs
was confirmed by restriction digestion and by direct
DNA sequencing with the use of the Sequenase 2.0 DNA
Sequencing Kit (United States Biochemical) or the au-
tomated fluorescent sequencing machine ABI 377 (PE
Biosystems).
Cell Culture and Transient Expression of Merlin
Proteins in Culture Cells
COS-7, Hela, and 293 cells (ATCC) were cultured in
Dulbecco’s modified Eagle’s minimum essentialmedium,
supplemented with 10% fetal bovine serum and anti-
biotics (Gibco), at 37C in a 5% CO2 humidified in-
cubator. Exponentially growing COS-7, Hela, and 293
cells were seeded 24 h before transfection. At 50% cell
confluency, DNA transfer was performed by liposome-
mediated gene transfer, with the use of either Effectene
reagent or Superfect reagent (Qiagen). Cells were incu-
bated for 3 h (Superfect) or overnight (Effectene) in the
presence of the DNA-liposome reagent and were washed
with PBS; fresh medium was then added. Cells were
assayed for protein production 24–72 h after transfec-
tion. Overnight exposure to Effectene did not show dif-
ferences in cell death, morphology, or protein expression
compared to a 3-h exposure to lipofect reagent Superfect
(Qiagen).
Antibodies
The merlin polyclonal antibodies N50 and C53 were
generated by injecting female New Zealand white rab-
bits with synthetic peptides conjugated to keyhole lim-
pet hemocyanin: N50 (YAEHRGRARDEAEMEYLK-C;
residues 192–209, including a carboxyl-terminal cyste-
ine residue) and C53 (C-LHNENSDRGGSSKHNTIK;
residues 561–578, including an amino-terminal cysteine
residue). N50 antibody was affinity-purified on peptide
columns by means of the HiTrap NHS–activated reagent
(Pharmacia Biotech). All other antibodies were com-
mercially available: rabbit polyclonal antimerlin anti-
body A-19 (Santa Cruz Biotechnology), mouse mono-
clonal anti-GFP antibody (Clontech, Boehringer-Mann-
heim), rhodamine- and Texas Red–coupled goat antir-
abbit antibodies, Oregon Green 488–coupled goat an-
timouse antibody, Texas Red–conjugated X phalloidin,
and anti-b-tubulin mouse monoclonal antibody (Molec-
ular Probes).
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Immunofluorescence and Microscopy
Transfected cells grown on untreated or poly-D lysine-
coated coverslips (Sigma) were fixed in 4% parafor-
maldehyde and permeabilized with 0.05% saponin
(Sigma). Fixed cells were incubated with 0.4–2.0 mg/ml
primary antibody. When staining for actin, we also
added a 1:40 dilution of Texas Red–conjugated anti-X
phalloidin. Cells were rinsed in PBS containing 1% Tri-
ton X-100; incubated with 1:500 dilution of the appro-
priate secondary fluorescent antibody; conjugated to ei-
ther rhodamine, Texas Red, or Oregon Green 488; and
then mounted in Prolong medium and DAPI (Molecular
Probes). Cells were visualized with a Zeiss epifluores-
cence microscope or with a Molecular Dynamics con-
focal laser-scanning microscope 2010. For analysis of
GFP expression and viability in cells, GFP-transfected
cells were incubated with propidium iodide (Molecular
Probes), washed with PBS, resuspended in culture media
without phenol red (Gibco), and visualized with the epi-
fluorescence microscope.
Preparation of Cell Extracts
Suspended COS-7 cells were collected 48–72 h after
transfection, washed with PBS, and resuspended in lysis
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Non-
idet P-40, 0.1% sodium deoxycholate, 0.1% sodium do-
decyl sulfate) containing proteinase inhibitors (1 mM
Pefabloc [Boehringer-Mannheim], 10 mg/ml aprotinin,
10 mg/ml leupeptin, and 10 mg/ml pepstatin). These were
used as the detached fractions. Attached cells were in-
cubated with lysis buffer for 30 min at 4C and were
used as the attached fractions. Protein concentrations
were determined by means of the BioRad DC Protein
Assay Kit.
Detergent Extraction
COS-7 transfected cells were extracted for 40–50 s
with 30-ml extraction buffer (50 mM MES, pH 6.4, 3
mM EGTA, 5 mM MgCl2, 0.5% Triton X-100). The
detergent-soluble material was precipitated with 85%
acetone overnight at 20C, and the pellet was recov-
ered after centrifugation at 14,000 g for 15 min at 4C.
Detergent-insoluble material was scraped in PBS con-
taining proteinase inhibitors and was centrifuged at
14,000 g for 15 min at 4C. All pellets were resuspended
in the same volume of Laemmli sample buffer.
Immunoblotting
Cell lysates were boiled in 1X Laemmli sample buf-
fer (2% SDS, 10% glycerol, 5% b-mercaptoethanol,
0.002% bromophenol blue, and 62.5 mM Tris HCL,
pH 6.8), loaded onto a 10% or 7.5% SDS-PAGE gel,
and electrotransferred onto polyvinylidene fluoride
(PVDF) membrane. Filters were blocked in PBS con-
taining 5% skim milk, incubated with 0.2 mg/ml primary
antibody in PBS containing 0.1% Tween 20 (PBS-T),
washed extensively with PBS-T, and incubated with 1:
3000 dilution of the appropriate secondary antibody.
After washing with PBS-T, detection was accomplished
with the use of horseradish peroxidase–coupled second-
ary antibodies (Amersham) and enhanced chemilumi-
nescence substrate (NEN) or by alkaline phospho-
tase–conjugated secondary antibodies and chemifluo-
rescence ECF substrate (Amersham) or biotin-conju-
gated secondary antibodies (Sigma), streptavidin and
32P-3DNA dendrimer (Genisphere).
Quantification of Western Blots
Radioactive and fluorescent blots were scanned with
the Molecular Dynamics STORM imager and quanti-
tated by means of the ImageQuant software program
(Molecular Dynamics). Luminescent blots were exposed
to film, digitized with the Silverscan III flatbed scanner
(La Cie), and quantitated with the National Institutes
of Health Image Program, by means of a calibrated step
tablet (Kodak).
Expression and Purification of GST Fusion Proteins
Logarithmically growing cultures of E. Coli BL21,
transformed with the pGEX-5X-2 recombinant plas-
mids, were incubated overnight at room temperature,
with 0.05 mM isopropyl-b-D-thiogalactoside. The cells
were pelleted and were resuspended in 1/20 volume ice-
cold PBS, containing 1% Triton X-100 and proteinase
inhibitors, and were sonicated on ice for 30 s. Cellular
debris was removed by centrifugation at 10,000 g for
15 min at 4C. The supernatant was applied to a glu-
tathione sepharose 4B column (Pharmacia Biotech) and
the GST fusion proteins were eluted with 5 mM reduced
glutathione in 50 mM Tris-HCL, pH 9.5. Purified pro-
teins were analyzed by separation on a 10% SDS-PAGE
gel stained with Commassie Blue and were quantified
with the BioRad Protein Assay Reagent. Purified pro-
teins were stored at 80C.
In Vitro Protein Binding Assays
The merlin pcDNA3 plasmids were used as template
for a T7-coupled transcription-translation system (Pro-
mega TnT kit) in the presence of 35S-methionine, and
radiolabeled protein was made. Samples of the TnT re-
actions were boiled in 1X Laemmli’s sample buffer and
were separated on a 10% SDS-PAGE gel. The dried gel
was exposed to film to determine the size, specificity,
and quantity of the radiolabeled protein. Known
amounts of radiolabeled protein (10–25 ml of a 100-ml
TnT rxn) were incubated with equal amounts of GST
or GST–merlin fusion proteins (5–25 mg) and were im-
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Figure 1 Merlin structural domains and the different cDNA
constructs used in the study. A, Predicted merlin structure. On the
basis of the primary sequence and homology to the ERM proteins,
merlin is predicted to consist of a globular amino terminus, an alpha-
helical central region, followed by a charged carboxyl-terminal domain
(Rouleau et al. 1993; Turunen et al. 1998). B, Details of the various
cDNA constructs. Numbers correspond to the aa position of isoform
1. All constructs had two versions that either were the natural N-
terminus or contained the GFP moiety fused to the N-terminus of
merlin (gray hexagon). The unblackened box corresponds to the spe-
cific C-terminus of isoform 2 (Arakawa et al. 1994). The position of
aa substitutions and deletions are indicated by inverted carets (∨)
(MacCollin et al. 1993; Bourn et al. 1994; Sainz et al. 1994; Evans et
al. 1995). Letters in the construct names correspond to the single-letter
designation for the aa. The left letter identifies the wild-type residue,
and the right letter identifies the mutant substitution. The constructs
DBB andMer559 were engineered to contain the analogousmutations,
a dominant-negative and activated allele, respectively, described else-
where for Drosophila merlin (LaJeunesse et al. 1998).
mobilized on glutathione-sepharose beads in TEN buffer
(10mMTris-HCL, pH7.5, 150mMNaCl, 5mMEDTA,
1% Triton X-100, 1 mg/ml BSA, and proteinase inhib-
itors) for 2–4 h at 4C. The supernatant was removed,
and the beads were washed four times with TEN buffer.
Protein bound to the beads was eluted by boiling in 2X
Laemmli’s sample buffer for 5 min. Samples were sep-
arated on a 10% SDS-PAGE gel. The dried gel was
analyzed by autoradiography and phosphoimagery, by
means of the STORM imager and the ImageQuant soft-
ware package.
In Vitro Microtubule Binding Assay
One hundred twenty-five micrograms of purified bo-
vine tubulin (Molecular Probes) were assembled into mi-
crotubules in vitro with 50 ml of 35S-labeled merlin pro-
tein in a total of 1 ml PGEM buffer (80 mM PIPES, 1
mM MgCl2, 1 mM EGTA, 1 mM GTP [Sigma], 30%
glycerol, pH 6.8), with 20 M paclitaxel (Molecular
Probes), for 30 min at 37C. Prior to incubation, 50 ml
were removed and labeled as the “total” fraction. After
assembly, the polymerized microtubules were collected
by centrifugation at 18,000 rpm in a Sorvall SS-34 rotor,
for 30 min at 30C. The supernatant was removed to a
fresh tube and was labeled “supernatant,” and the mi-
crotubule pellet was resuspended in 1 ml PGEM buffer
and was labeled “pellet.” Fifty microliters of each frac-
tion were separated on a 12% SDS-PAGE gel. The dried
gel was analyzed with the use of the STORM imager
and the ImageQuant software package.
Results
Construction of Wild-Type and Mutant Merlin Proteins
To identify biological differences between mutant and
wild-type merlin, we constructed GFP-tagged and -un-
tagged expression plasmids for the two wild-type merlin
isoforms; for the N-terminal domain, which is analo-
gous to a common NF2-associated nonsense mutation
Arg341X; for the unique C-terminal domain; and for
five NF2-associated missense mutants (fig. 1). In addi-
tion, we designed mammalian expression plasmids for
a “dominant-negative” and for an “activated” form of
merlin, DBB and Mer559, respectively, which have been
characterized elsewhere (LaJeunesse et al. 1998) in the
Drosophila homologue of merlin. The mammalian ex-
pression constructs were confirmed to produce stable
proteins of the predicted size by in vitro transcription/
translation (fig. 2A). As shown in figures 3 and 4, west-
ern blot analysis revealed that the tagged and untagged
wild-type merlin products migrate as a distinct doublet
∼70 kD for the untagged protein (fig. 3A) and ∼100 kD
for the GFP-tagged protein (fig. 3A). This pattern of
migration was demonstrated to be due to phosphory-
lation of merlin, with the lower migrating band corre-
sponding to the dephosphorylated form (Shaw et al.
1998). We observed both migrating species for both the
tagged and the untagged constructs containing the mis-
sense mutations and did not observe any difference in
the phosphorylated/dephosphorylated ratio between the
wild-type and missense proteins, which suggests that the
mutant proteins produce phosphorylated and dephos-
phorylated products in vivo similar to the wild-type pro-
tein (fig. 3A). For all quantitative assays done in this
study, we included both migrating species of merlin in
all calculations.
Subcellular Distribution of Wild-Type and Mutant
Merlin
To investigate whether mutations in merlin affect
proper subcellular distribution of the protein, we tran-
siently transfected HeLa, 293, and COS-7 cells with the
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Figure 2 Analysis of NF2 mutations on merlin protein interactions in vitro. The ability of wild-type and mutant merlin proteins to form
intermolecular complexes was quantitated by means of a GST-fusion binding assay. A, 35S-labeled wild-type and mutant merlin proteins produced
in vitro. A 5-ml aliquot of each reaction (input) was separated by SDS-PAGE analysis, and the amount of labeled full-length product was
quantitated on a phosphoimager. Each radiolabeled protein (10–20 ml) was incubated with immobilized GST-merlin. The total amount of bound
radiolabeled protein (output) was run on an SDS-PAGE gel and quantitated on a phosphoimager. The amount of radiolabeled protein bound
to GST-merlin was calculated as a percentage of the total radiolabeled input for each reaction. These percentage values were used as data points
for table 1. B, The reciprocal in vitro binding assay. In vitro translated 35S-labeled wild-type merlin (25 ml) was incubated with equal amounts
of immobilized GST-merlin containing NF2 mutations. The percentage of total radiolabeled merlin bound to the GST fusion proteins was
determined by phosphoimage analysis, as described above, and these percentage values were used as data points for table 1. Mutant K79E and
DCterm gave inconsistent results between the two reciprocal assays. The position of molecular mass standards is indicated, in kilodaltons, on
the left.
merlin expression constructs and observed the patterns
of merlin localization in both fixed and live cells. En-
dogenous merlin in these cells was detected clearly by
western blot (fig. 3A, vector lane) but was difficult to
visualize by immunohistochemistry (fig. 5F), which sug-
gests a low endogenous level of merlin expression. Poly-
clonal anti-Nterm, A-19, and anti-Cterm, C53, anti-
bodies were used to stain for untagged merlin expression
in fixed cells, and GFP autofluorescence was used to
study protein localization in live cells. The results were
similar for the tagged and untagged proteins and for the
various cell types, and were consistent for multiple in-
dependent transfection experiments. The two wild-type
isoforms localized to the plasma membrane and were
particularly abundant in the submembranous regions of
filopodia, microspikes, and ruffling membrane (figs. 5A
and6B). In addition to the membrane localization, in a
large fraction of cells merlin also localized to punctate
Figure 3 Analysis of mutant merlin expression on cell attachment. A, Immunoblot of attached and detached COS-7 cells transfected with
wild-type and mutant cDNA constructs. Forty-eight hours after transfection the amount of transfected merlin protein expressed in detached
(lanes D) and attached (lanes A) cells was determined by western analysis, with a 1:1000 dilution of polyclonal antimerlin antibody A-19 for
the untagged constructs and a 1:1000 dilution of monoclonal anti-GFP antibody for the tagged constructs. The two bands indicated by arrows
correspond to the phosphorylated (top) and dephosphorylated (bottom) species of endogenous merlin. Molecular mass standards are indicated,
in kilodaltons, on the left. B, Quantification, by means of a fluorescent imager and the ImageQuant software program, of amount of transfected
protein in detached and attached fractions. Both species of merlin were included in the calculations. The percentage of total transfected protein
present in the detached cells was determined for each construct (D/[AD ]). The average value for each construct was calculated from at least
four separate experiments, and the SEM is depicted for each line. Statistically significant differences from isoform 1, determined by the student
t-test ( ), are indicated with an asterisk (*).P ! .02
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Figure 4 Analysis of NF2 mutations on protein solubility.A, Immunoblot of soluble (S) and insoluble (I) fractions of COS-7 cells transfected
with untagged cDNA constructs. Transfected cell lysates were recovered 48 h after transfection, and equal amounts of soluble and insoluble
fractions were analyzed, by western analysis, with 1:1000 dilution of polyclonal anti-merlin antibody A-19. Molecular mass standards are
indicated, in kilodaltons, on the left. B, Quantification, by means of a fluorescent imager and the ImageQuant software program, of amount
of transfected protein in the soluble and insoluble fractions. The percentage of total transfected protein that was present in the Triton X-100
soluble fraction was calculated for all constructs (S/[SI]). Average value for each construct was calculated from multiple experiments and the
SEM is indicated for each line. Statistically significant differences from isoform 1, determined by the student t-test ( ), are indicated withP = .03
an asterisk (*).
cytoplasmic granules (figs. 5B and6A). The localization
of the N-terminal and C-terminal truncations of merlin
differed markedly from the full-length protein. The ERM
homology domain DCterm localized mainly to the nu-
cleus, although some protein did localize to the plasma
membrane and was never seen as cytoplasmic granules
(6D). The C-terminal half of merlin DNterm was local-
ized diffusely in the cytoplasm and showed no locali-
zation to the dynamic regions of the membrane (6C).
Of the five missense mutants, only two displayed an
Figure 5 293 cells expressing untagged wild-type and mutant forms of merlin. Untagged wild-type merlin shows the same localization
pattern as GFP-tagged merlin (A and B). The mutant T352M localizes to microspikes and filopodia and to cytoplasmic granules, similar to
wild-type merlin (C). Overexpression of wild-type merlin in cells leads to an increase in membrane extensions (A) compared to cells transfected
with vector alone (F), whereas the dominant-negative mutant DBB often stained round cells with no membrane extensions (D). The mutant
D118 does not affect cell morphology (E). Cells were stained with a 1:500 dilution of antimerlin antibody A-19 and Texas Red–conjugated
secondary antibody and were visualized by confocal microscopy. Bar equals 5 mm.
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abnormal cellular distribution pattern. The K79E mis-
sense mutant was strongly localized to the perinuclear
cytoplasm, with only minor staining at the plasma
membrane (6E). The single aa deletion D118 protein
showed diffuse cytoplasmic staining (figs. 5E and6F). Of
the remaining mutant proteins, the missense L535P mu-
tant (6J) and the dominant-negative mutant DBB (fig.
5D) showed submembranous membrane localization
but were rarely seen as cytoplasmic granules, which
matched the localization pattern of the DBB mutant pro-
tein reported in Drosophila (LaJeunesse et al. 1998).
Mutants N220Y (data not shown), T352M (fig. 5C),
and Mer559 (6I) localized strongly to the submembran-
ous regions in membrane extensions, in addition to cy-
toplasmic granules in some cells.
Studies of the subcellular distribution of Drosophila
merlin found the protein initially localized to the
membrane but then internalized to form punctate cy-
toplasmic structures (LaJeunesse et al. 1998). We had
observed merlin-rich punctate cytoplasmic structures in
a subset of the transfected cells and wanted to determine
if, over time, human merlin also moved from the
membrane into cytoplasmic granules. Thus, we moni-
tored the subcellular localization of the GFP-taggedmer-
lin proteins in live cells during a period of 48 h, to
determine if merlin localization altered with time. No
time-dependent changes in protein localization were ob-
served (data not shown). Since three of the five missense
mutants are indistinguishable from wild-type in cellular
localization, proper targeting of merlin to the plasma
membrane may not be sufficient for tumor-suppressor
activity, although it may be necessary.
Cell-Adhesion Properties of Merlin Proteins
Although morphology showed variability from cell to
cell, we observed a general trend of altered morphology
in merlin-transfected cells compared to cells transfected
with vector alone (figs. 5F and6H). Cells transfectedwith
the wild-type isoforms and the mutants N220Y and
T352M showed an increase in membrane spikes, long
filopodia, and surface blebs, and some cells had ex-
tremely large surface areas (figs. 5A, 5C, and6B). In
contrast, cells overexpressing full-lengthGFP-moesindid
not display these morphological changes (6G). Cells ex-
pressing the activated mutant Mer559 often appeared
as round cell bodies with multiple extremely long, thin
cellular processes (6I), whereas cells expressing the dom-
inant-negative mutant DBB were often completely round
with no cellular extensions (fig. 5D). Cells expressing
the mutants L535P and DCterm showed an increase in
microspikes but seldom had extremely long cellular pro-
cesses (figs.6D and6I). Merlin constructs that mainly lo-
calized to the cytoplasm led to no noticeable morpho-
logical changes; cells expressing the missense protein
D118 (figs. 5E and6F) or DNterm (6C) were similar in
cell shape to vector-transfected cells (figs. 5F and6H).
These qualitative morphological changes suggested to
us that merlin may be involved in cell-matrix interac-
tions. To determine if NF2 mutant proteins could alter
cell-matrix interactions, we assayed the adhesion prop-
erties of cells expressing the wild-type andmutantmerlin
proteins. COS-7 cells were transiently transfected with
merlin expression constructs, and 48 h posttransfection
detached and attached cell fractions were collected.
Equal amounts of attached and detached cell lysates
were analyzed by immunoblotting, to determine the per-
centage of total merlin protein found in the detached
fraction. Cells expressing the mutant merlin proteins
K79E, N220Y, T352M, L535P, DNterm, and DCterm
showed an increased tendency to detach from the plate
surface compared to cells expressing either wild-type
merlin isoforms, which were seldom found in the de-
tached fraction (fig. 3A). Interestingly, the mutant
proteins DBB and Mer559, which correspond to the
Drosophila dominant-negative mutation and to the ac-
tivating mutation, respectively, showed opposite effects
on the adhesion property of the cell. The activating mu-
tation behaved similarly to the NF2-associated mutant
proteins by decreasing cell adhesion, whereas the dom-
inant-negative mutation had no effect on adhesion (fig.
3A). To test for reproducibility of this assay, the exper-
iment was performed four separate times with both the
tagged and untagged proteins. Although the absolute
percentage of detached cells was variable between the
experiments, the general trends were consistent, and dif-
ferences between the wild-type and the mutant proteins
were statistically significant with the student t-test (fig.
3B). Interestingly, only the lower migrating merlin band
was found in the detached fraction for wild-type protein,
which suggests that only dephosphorylated wild-type
merlin is present in the detached cells (fig. 3A). In con-
trast, the upper migrating band was present in the de-
tached fraction of some of the mutant proteins, such as
L535P (fig. 3A), which implies that the phosphorylated
form is no longer restricted from the detached cells.
However, these results were not consistent among the
four experiments.
To test for the possibility that the increase in detach-
ment for the mutant-expressing cells was due to in-
creased cell death, detached cells were examined for vi-
ability by staining with propidium iodide. More than
80% of the detached cells were viable by this assay, and
there was no distinguishable difference in viability be-
tween the cells expressing mutant merlin and the wild-
type (data not shown).
Figure 6 293 cells expressing GFP-tagged wild-type and mutant forms of merlin. Wild-type merlin (A and B) and the mutants Mer559
(I) and L535P (J) localize to submembranous regions, especially microspikes and filopodia (B, arrow), and wild-type merlin is sometimes seen
as granules throughout the cytoplasm (A, arrow). In contrast, the carboxyl-terminal half of isoform 1 localizes to the cytoplasm (C), and the
amino-terminal half of merlin is seen mainly in the nucleus (D). The NF2 mutations K79E (E) and D118 (F) alter the localization of the protein,
with the protein localized mainly in the perinuclear cytoplasm with little or no membrane localization. Overexpression of wild-type merlin in
cells (A and B) leads to an increase in membrane extensions and cell spreading compared to expression of GFP alone (H) or cells expressing
GFP-tagged full-length moesin (G). Overexpression of NF2 mutant proteins affects cell morphology in varying degrees, with the activated
mutant Mer559 leading to round cell bodies with extremely long membrane extensions (arrow, I), whereas the deletion mutant D118 does not
affect cell morphology (F). Cells were visualized by confocal microscopy. Bar equals 5 mm.
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Cytoskeletal Interactions of Wild-Type and Mutant
Merlin
It is possible that the effect on cell adhesion and mor-
phology by merlin proteins is mediated through inter-
actions with the actin cytoskeleton. The ERM proteins
bind F-actin through a highly conserved region in the
C-terminal domain (Turunen et al. 1994), and over-
expression of this domain in transfected cells disrupts
actin-based cytoskeleton organization (Edwards et al.
1994). Although merlin lacks this conserved actin-bind-
ing domain, studies have demonstrated that merlin col-
ocalizes with cortical actin and that chemical disruption
of the actin cytoskeleton leads to a redistribution of mer-
lin in the cell (den Bakker et al. 1995b; Deguen et al.
1998). To investigate whether mutant merlin protein
could disrupt actin cytoskeleton organization through
aberrant merlin-cytoskeletal interactions, we studied the
distribution of actin in 293 and CHO cells transfected
with GFP-tagged wild-type and mutant merlin proteins
by immunostaining with Texas Red–conjugated phal-
loidin. Wild-type and mutant merlin, which showed nor-
mal subcellular distribution, colocalized with actin at the
motile regions of the plasma membrane-filopodia, ruf-
fling edges, and microspikes, but showed no colocal-
ization with actin stress fibers (data not shown). The
merlin mutations that decreased cell adhesion had no
effect on organization or distribution of the actin cy-
toskeleton (data not shown).
To further our studies of possible effects on merlin-
cytoskeletal interactions by NF2 mutations, we per-
formed cell fractionation assays on merlin-transfected
cells. It is well established that nonionic detergent ex-
traction procedures preserve the cytoskeleton and isolate
tightly linked cytoskeletal proteins in the insoluble frac-
tion (Algrain et al. 1993). After mild nonionic detergent
extraction, cells expressing the different merlin con-
structs were stained with the antimerlin antibodies A-
19 and C53, to determine the solubility of the wild-type
and mutant proteins. The wild-type isoforms and mu-
tants N220Y, T352M, DBB, and Mer559 displayed no
noticeable change in overall protein subcellular locali-
zation or intensity of staining after detergent extraction,
which suggests that these proteins are linked to cyto-
skeletal elements. In contrast, the D118 and DNterm
mutant proteins display an altered staining pattern after
mild detergent extraction, changing from a diffuse cy-
toplasmic to a strong punctate perinuclear localization,
after detergent extraction (data not shown). The K79E
mutant protein shows a change in cellular localization
after extraction similar to but less pronounced than the
D118 mutant protein. Furthermore, the DCterm and the
L535P mutant proteins display an overall decrease in
intensity of staining, which implies that these mutations
increased the solubility of the protein (data not shown).
To confirm these observations, quantitative immunoblot
analysis of equal amounts of soluble and insoluble frac-
tions from the transfected cells were performed. The im-
munoblotting confirmed that the missense mutations
K79E, D118, and L535P and the deletion of the N- or
C-terminal domains increased the solubility of the pro-
tein, which suggests that these mutations decrease the
stability of merlin-cytoskeletal interactions (fig. 4A).
Since detergent extraction experiments can be difficult
to reproduce, the experiment was performed several
times, and the differences in solubility from wild-type
were statistically significant for the mutants K79E,
D118, L535P, and DCterm (fig. 4B). It is interesting to
note that the main species of merlin recovered in the
soluble fraction is the dephosphorylated form.
Last, we performed in vitro microtubule binding as-
says with radiolabeled wild-type and mutant merlin pro-
teins. Xu and Gutmann (1998) reported a microtubule-
binding region in the N-terminal domain of merlin,
which was normally masked in the wild-type protein but
was exposed in NF2 mutant proteins containing C-ter-
minal truncations, exon deletions, and an L64P missense
mutation. They hypothesized that merlin protein that
exists in an “open” conformation would be defective in
growth suppression. We wanted to investigate whether
the majority of missense mutations in merlin would alter
the folding of the full-length molecule such that normally
“masked” binding domains would be revealed in the
mutant molecule. Purified bovine tubulin was polymer-
ized in the presence of in vitro transcribed and translated
radiolabeled merlin protein. Polymerized microtubules
and tightly linked proteins were pelleted by high-speed
centrifugation, and proteins left in the supernatant were
unassociated with microtubules. Equal amounts of each
fraction were loaded on an SDS-PAGE gel, and the
amount of radiolabeled merlin found in each fraction
was determined by phosphoimage analysis. No signifi-
cant differences in microtubule binding were seen be-
tween the wild-type isoforms 1 and 2 (14% and 15%
bound, respectively) and the missense mutants K79E,
N220Y, T352M, and L535P (18%, 18%, 14%, and
10% bound, respectively). In fact, contrary to other re-
ports, the N-terminal domain (aa 1–341) did not display
significant microtubule binding (8% bound), whereas
the C-terminal domain (aa 342–595) showed no micro-
tubule binding activity (0.9% bound). Furthermore, im-
munofluorescence staining of cells transiently transfected
with GFP-merlin fusion constructs with antitubulin an-
tibody showed no colocalization of merlin and micro-
tubules (data not shown).
Merlin-Merlin Interactions
It has been demonstrated by the two-hybrid system
and in vitro binding assays that merlin could form hom-
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Table 1
Summary of Merlin Dimerization In Vitro
Protein Construct
Dimerization with Wild-Type Merlin
Relative to Isoform 1a
GST (control)
Isoform 1 1
K79E 2.181.9
D118 .21.09b
N220Y .94.5
T352M .76.03
L535P 2.36.58b
DBB 2.931.29b
Mer559 6.172.36b
DCterm .58.71
DNterm .001.001b
Moesin .07.02b
a Amount of mutant merlin interaction with wild-type
merlin was calculated as a fraction of the dimerization of
isoform 1. Data points are representative of three experi-
ments and the SD for each point is shown.
b Statistically significant, determined by the student t-test
( ).P  .05
odimers, and it was hypothesized that self-association
could be a form of functional regulation (Gutmann et
al. 1998; Scoles et al. 1998). To determine if NF2 mu-
tations could disrupt merlin self-interactions, we used
an in vitro affinity precipitation method to quantitate
the binding of wild-type merlin to itself and missense
forms of merlin. In a set of experiments, radiolabeled
wild-type merlin was generated in vitro and equal
amounts of radiolabeled product were incubated with
equal amounts of immobilized, bacterially expressed
GST-merlin proteins, with or without missense muta-
tions. The GST moiety showed little or no binding of
radiolabeled merlin (fig. 2B). The strength of the merlin
interactions was quantitated by measuring the percent-
age of total radiolabeled protein that remained bound
to the GST fusion proteins after extensive washing. The
reciprocal experiment of measuring the amount of in
vitro generated radiolabeled mutant merlin bound to
immobilized GST–wild-type merlin was also performed
(fig. 2A). The different radiolabeled merlin constructs all
showed little or no binding to the GST moiety (fig. 2A
shows the result for Mer559). Because the amount of in
vitro generated radiolabeled product differed between
the merlin constructs, the total amount of radiolabeled
protein input for each incubation was determined by
quantification on a phosphoimager (fig. 2). The amount
of bound radiolabeled protein was calculated as a per-
centage of the total radiolabeled input for each separate
incubation, thereby normalizing the results to allow di-
rect quantitative comparison of the strength of binding
among the different merlin constructs. The experiments
were performed three times, and the results were con-
sistent for all constructs except K79E and DCterm, ren-
dering the results for these two proteins inconclusive (fig.
2A and 2B). In addition, the GST-isoform 1 displayed
greatly increased binding of radiolabeled isoform 2 com-
pared to isoform 1 (fig. 2A); however, the reciprocal
binding experiment has not yet been performed to con-
firm this result. Five of the remaining seven mutant mer-
lin proteins showed aberrant homodimerization. One
missense construct, L535P, displayed a threefold increase
in binding to wild-type merlin in vitro (table 1), which
suggests that this aa substitution increased merlin di-
merization. In contrast, the D118 mutant protein gave
a fivefold decrease in binding to wild-type merlin, and
DNterm showed a complete inability to bind full-length
merlin, which implicates the amino terminus as an es-
sential domain for homodimerization (table 1). The
dominant-negative DBB mutation in merlin and the ac-
tivated mutant Mer559 both demonstrate an increased
ability to dimerize with wild-type merlin (table 1), which
suggests that homodimers may be an active form of the
protein. The differences in binding ability in vitro are
not likely to be due to gross differences in protein trans-
lation and stability among the GST fusion constructs or
in vitro translated products, since by SDS-PAGE anal-
ysis, all merlin constructs displayed the expected-size
protein products and showed similar protein stability
over time (data not shown). Therefore, missense-con-
taining mutations in merlin can have opposite effects on
merlin homodimerization. Interestingly, we observed
that full-length merlin binds more strongly to another
full-length molecule than to either the amino- or car-
boxyl-terminal domain alone, which is opposite to that
seen for the ERM proteins (Magendantz et al. 1995;
Bhartur and Goldenring 1998), thereby demonstrating
that merlin may be functionally regulated in a different
manner from the ERM proteins. In addition, we ob-
served that native merlin did not bind the closely related,
full-length moesin protein (table 1).
Merlin-EBP50 Interactions
From a two-hybrid screen for merlin interactors and
an affinity precipitation experiment for ERM binding
partners, two groups independently identified a phos-
phoprotein, EBP50, which associated strongly with
ERM and merlin through the highly conserved amino-
terminal domain (Reczek et al. 1997; Murthy et al.
1998). Murthy et al. also reported that merlin containing
the missense mutation N220Y showed reduced binding
to EBP50, which suggests that this protein interaction
may be important for merlin function. To determine if
other NF2-associated mutations also affected merlin-
EBP50 interactions, we used an affinity precipitation as-
say to quantitate the ability of mutant forms of merlin
to bind EBP50. In vitro translated, radiolabeled EBP50
was incubated with wild-type and mutant merlin GST-
fusion proteins immobilized on GSH beads. The amount
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Figure 7 NF2 mutations decrease binding of merlin to EBP50 in vitro. A, Binding of mutant merlin proteins to EBP50, as was determined
by means of a GST fusion binding assay. In vitro 35S-labeled full-length EBP50 (10 ml) was incubated with equal amounts of immobilized GST-
merlin fusion proteins containing NF2 mutations. GST-merlin and GST-moesin fusion proteins were used as positive controls for EBP50 binding.
B, Amount of EBP50 bound to the mutant proteins, calculated as a fraction of EBP50-isoform 1 binding for one experiment, and the calculated
value is shown below each lane.
of EBP50 bound to the GST-merlin proteins was quan-
titated by phosphoimage analysis of SDS-PAGE gels. In
vitro translated EBP50 produced a distinct doublet ∼50
kD (fig. 7A), which matches a report (Reczek et al. 1997)
that stated that endogenous placental EBP50 produces
three species ∼50–53 kD because of differential phos-
phorylation. Therefore, in vitro generated EBP50 seems
to undergo posttranslational modification similar to the
endogenous protein. Binding of both EBP50 bands to
merlin was quantified, and no differences in merlin bind-
ing between the two EBP50 species were detectable (fig.
7A). We confirmed the ability of EBP50 to bind wild-
type merlin and moesin and found that four of five NF2-
associated missense mutations of merlin decreased
EBP50 binding by 35%–65% (fig. 7B). In addition, we
confirmed that the ERM homology domain DCtermwas
sufficient for binding EBP50, as has been reported else-
where (Murthy et al. 1998). We also found that a mis-
sense mutation in the extreme carboxyl terminus at po-
sition 535 of merlin reduced binding by 50% compared
to wild-type, a region which was not thought to be nec-
essary for EBP50 interaction (fig. 7B). To confirm our
results, the binding experiment was repeated. Although
the overall amount of binding of EBP50-merlin was too
low to allow sensitive quantification, the results were
consistent in that only wild-type merlin, moesin, and the
mutants T352M, DCterm, and DNterm gave detectable
binding to EBP50, whereas the mutants K79E, D118,
N220Y, L535P, and DBB displayed no detectable binding
of EBP50 (data not shown). It is worth noting that the
effect of NF2 mutations on merlin-EBP50 binding does
not correlate with their effect on merlin-merlin inter-
actions (table 2).
Discussion
In this study, we used five NF2-associated missense mu-
tations and one truncating mutation to identify cellular
and molecular activities of the protein that are likely to
be necessary for merlin tumor-suppressor action. Of all
the cellular assays we performed, the most striking result
was the effect on cell adhesion due to mutant protein
expression. The expression of five of six NF2 mutant
proteins resulted in a significant decrease in cell adhe-
sion, which was observed as an increase in transfected
cells detaching from the substratum. In contrast, en-
dogenous and transfected wild-type merlin was seldom
seen in detached cells. In agreement with our results,
Koga et al. (1998) reported that human fibroblasts mi-
croinjected with mutant merlin constructs, containing
either NF2-causing truncating mutations or exon dele-
tions, would round up and detach from the substratum.
Furthermore, it has been shown that STS26T cells trans-
fected with antisense merlin oligonucleotides to give
complete loss of merlin protein also detached from the
substratum, in addition to displaying an increase in cell
proliferation (Huynh and Pulst 1996). Together, these
experimental results suggest that tumorigenesis may re-
sult from disruption of cell-matrix attachment because
of a complete loss of merlin protein or because of the
expression of a mutant merlin protein defective for the
cell-adhesion function of wild-type merlin protein. It is
well known that cell adhesion in adherent cells has an
important function for normal cell growth; in fact, an-
chorage-independent growth is a criterion for cell trans-
formation (Hynes 1992; Nur et al. 1992). Cultured NF2
Schwann cells, containing either truncating or missense
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Table 2
Summary of Molecular and Cellular Differences between Mutant and Wild-Type Merlin Proteins
Mutant Protein Cell Localization Protein Solubilitya Cell Adhesion Dimerization EBP50 Binding Phenotype
K79E Cytoplasmic Increasedb Decreasedb Inconclusive Decreased Sporadic schwannoma
D118 Cytoplasmic Increasedb NS Decreasedb Decreased Severe NF2
N220Y Membrane NS Decreasedb NS Decreased Severe and mild NF2
T352M Membrane NS Decreasedb NS NS Severe NF2
L535P Membrane Increasedb Decreasedb Increasedb Decreased Mild NF2
DCterm Nuclear Increasedb Decreasedb Inconclusive NS Severe NF2
DNterm Cytoplasmic Increased Decreasedb Decreasedb NS ND
DBB Membrane NS NS Increasedb Decreased Dominant-negative
Mer559 Membrane NS Decreasedb Increasedb ND Activated
NOTE.—NS = no significant difference from wild type; ND = not determined.
a Each box describes the result for the mutant protein as compared to the wild-type merlin protein in the corresponding assay.
b Denotes statistical significance ( ) for the difference between mutant and wild-type values, with the use of the student t-test.P  .05
NF2 alleles, lack contact inhibition of growth and dis-
play anchorage-independent growth and increased cell
proliferation (Rosenbaum et al. 1998), whereas over-
expression of full-length merlin in Ras-transformed fi-
broblast suppresses anchorage-independent growth and
restores contact inhibition of cell growth (Tikoo et al.
1994). Therefore, we hypothesize that merlin acts as a
positive regulator of cell-matrix attachment and that dis-
ruption of this activity is an initial step in tumor
progression.
We investigated several possible molecular mecha-
nisms by which merlin could regulate cell attachment.
The various mutant merlin proteins were analyzed for
their interaction with the cytoskeleton, since endoge-
nous merlin has been shown to colocalize with several
cytoskeletal elements, including F-actin, keratohyalin
granules, and intermediate filaments (den Bakker et al.
1995a; Gonzalez-Agosti et al. 1996), and such inter-
actions are likely to be involved in cell-matrix signaling
pathways. Consistent with a protein associated with the
cytoskeleton, we and others have demonstrated that
wild-type merlin is mainly detergent insoluble (Deguen
et al. 1998). We observed no change in merlin subcel-
lular localization or intensity of staining in cells ex-
tracted with nonionic detergent, and western blot anal-
ysis of detergent soluble and insoluble fractions showed
that 190% of merlin is retained in the insoluble fraction.
In contrast, 55% of the NF2 mutant proteins displayed
a significant increase in detergent extractability, indi-
cating a relaxed association with the cytoskeleton. Fur-
thermore, the mutant proteins K79E, D118, DCterm,
and DNterm, which fail to localize properly to the
plasma membrane and thus do not colocalize with cor-
tical actin, all demonstrated a significant increase in pro-
tein solubility, further supporting the contention that
these mutant proteins do not form stable interactions
with the cytoskeleton. However, merlin protein solu-
bility did not correlate with the protein’s effect on cell
adhesion, since two NF2mutant proteins that decreased
cell adhesion—N220Y and T352M—displayed no in-
crease in detergent solubility and/or difference in sub-
cellular localization compared to wild-type (table 2).
Thus, merlin regulation of cell adhesion is not likely to
be mediated simply through interaction with the actin
cytoskeleton.
One possible mechanism that may account for the
differences we observed between wild-type and mutant
merlin proteins is differential phosphorylation. Evi-
dence from several in vitro and in vivo studies of the
closely related ERM proteins suggests a model where
inactive ERM proteins in the cytoplasm are activated
by phosphorylation of a conserved threonine in the car-
boxyl terminus, causing translocation of the activated
form to the plasma membrane (Nakamura et al. 1995;
Hirao et al. 1996; Serrador et al. 1997; Matsui et al.
1998; Hayashi 1999). Merlin also contains this con-
served threonine at position 576, and, likewise, in vivo
merlin exhibits both phosphorylated and dephosphor-
ylated forms due to phosphorylation of serine and/or
threonine residues (Takeshima et al. 1994; Shaw et al.
1998). The ratio of the phosphorylated and dephos-
phorylated forms of merlin in cultured cells are affected
by cell adhesion. Loss of adhesion results in a complete
dephosphorylation of merlin, whereas reattachment of
cells to a substrate leads to a rapid increase in the phos-
phorylated species (Shaw et al. 1998). In this study we
found, by western analysis, that the five missense mu-
tants produced both the phosphorylated and dephos-
phorylated species and that detached cells only express
the dephosphorylated form of wild-type merlin. How-
ever, we sometimes observed, by western analysis, the
presence of the phosphorylated form of the missense
mutants K79E, T352M, and L535P in the detached
fraction, a condition we never saw for the two wild-
type isoforms. Since the expression of these mutant pro-
teins in cells causes loss of adhesion, and since the phos-
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phorylated form of thesemutants is abnormally retained
in the detached cells, these results suggest that the phos-
phorylation of these mutant proteins may no longer be
responsive to environmental cues, such as changes in
cell spreading and attachment, which may lead to im-
proper regulation of tumor-suppressor function. It will
be interesting to determine if the addition of phospha-
tase inhibitors to cell cultures modulates merlin’s effect
on cell adhesion. In a recent study, the presence of phos-
phatase inhibitors in homogenized cells was demon-
strated to increase the percentage of merlin recovered
in the insoluble fraction, which suggests that merlin is
translocated from the insoluble to the soluble fraction
by dephosphorylation (Maeda et al. 1999). Under this
model, we would expect to see a decrease in the ratio
of phosphorylated to dephosphorylated merlin for
mutants that showed increased solubility. We did not
observe any significant difference in the ratio of total
phosphorylated/dephosphorylated forms between the
wild-type and the missense mutants.
Intriguingly, four of the five disease-causing missense
mutants, as well as the dominant-negative Drosophila
mutant DBB, displayed decreased binding to EBP50, a
protein that binds all the MERM proteins (Murthy et
al. 1998; Reczek and Bretscher 1998) (table 2). EBP50
is the human homologue of rabbit NHE-RF, a cofactor
that has been shown to mediate protein kinase A in-
hibition of the renal Na-H exchanger NHE3 in cul-
tured cells (Yun et al. 1997). The physiological impor-
tance of merlin-EBP50 interaction remains highly
speculative, but it is interesting to note that it has been
well documented that stimulation ofNa-H exchang-
ers is associated with increased cell proliferation and
differentiation in response to growth factors and mi-
togenic agents (Ritter et al. 1997). We found no direct
correlation between the strength of EBP50-merlin in-
teractions and any of the cellular phenotypes we as-
sayed; however, our finding that 63% of the mutant
proteins studied reduced merlin-EBP50 binding merits
further investigation into the possibility that this inter-
action is a necessary but not sufficient component of
merlin tumor-suppressor function.
Another merlin-protein interaction that may be a con-
tributing factor in merlin regulation of cell growth is
merlin homodimerization. This hypothesis was sug-
gested by Sherman et al. (1997), who demonstrated that
alterations in the C-terminus that abolished merlin
growth suppression also resulted in no merlin self-as-
sociation. However, to date, no single aaNF2mutations
have been shown to alter merlin self-association. In this
report, we demonstrated that two NF2-associated mis-
sense mutations—D118 and L535P—significantly al-
tered the ability of the full-length mutant molecule to
dimerize with wild-type merlin (table 2). Surprisingly,
the twomissense mutations had opposite effects onmer-
lin interaction. Although the D118 mutation almost
abolished merlin dimerization, the missense L535P
greatly increased dimerization, implicating regulation of
merlin self-association as an important component of
merlin function. In support of this, the DBB mutation
in merlin and the merlin mutant Mer559, genetically
defined as a dominant-negative allele and a “gain-of-
function” allele in Drosophila, respectively (LaJeunesse
et al. 1998), both demonstrate an increased ability to
dimerize with wild-type merlin, which suggests that
homodimers may be an active form of the protein. In
this model, functionally defective merlin that can form
homodimers with remaining wild-type molecules and
mutant merlin that is unable to dimerize could both
lead to a decrease in merlin activity. Overall, all of the
merlin-protein interactions we assayed—cytoskeletal,
EBP50, and homodimerization—were disrupted byNF2
mutations, but none of the changes was correlated with
another or with the cell-adhesion phenotype. Thus, it
is likely that merlin acts within a complex of molecules
and that disruption of any of several interactions by
NF2 mutations leads to abnormal cell growth.
In light of the observation that mutations in merlin
can greatly alter cell adhesion, a potentially fruitful area
of investigation may be in merlin direct interaction with
adhesion transmembrane proteins. Recently, merlin was
shown to partially colocalize and coimmunoprecipitate
with the b1-integrin transmembrane receptor in differ-
entiating Schwann/neuron cell cultures (Obremski et al.
1998). b1-integrin binding to the basal lamina and the
actin cytoskeleton have been implicated as part of a
signal transduction complex necessary for Schwann cell
myelination (Fernandez-Valle et al. 1994). Like merlin,
overexpression of integrins can suppress anchorage-
independent growth and prevent abnormal cell growth
(Giancotti and Ruoslahti 1990). Thus, NF2mutant pro-
teins may have aberrant interactions with b1-integrins,
thereby altering the transduction of signals from the
extracellular matrix necessary for Schwann cell differ-
entiation and growth. This model could easily be tested
by determining the ability of NF2 mutant merlin to
coimmunoprecipitate with b1-integrin from cells and
investigating for aberrant localization and responses of
b1-integrin in NF2 Schwann cells.
Last, our demonstration of cellular phenotypes as-
sociated with exogenous expression of NF2 mutant al-
leles shows that these missense mutations may act in a
dominant manner.We found that the decrease in cellular
adhesion by mutant NF2 proteins could be a dominant
effect, since COS-7 cells contain two wild-type NF2
alleles and have low levels of endogenous merlin ex-
pression detectable by western blotting. However, the
mutant alleles may be acting as loss-of-function muta-
tions in the adhesion phenotype. If overexpression of
wild-type merlin causes greatly increased cell attach-
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ment, whereas mutant merlin has no effect on cell
attachment, the results would be similar to what we
observed in this study. In agreement with a dominant
mode of action for mutant NF2 alleles, Koga et al.
(1998) reported that loss of cell attachment still oc-
curred whenNF2 deletionmutants andwild-typemerlin
were coexpressed in fibroblasts. Experimental evidence
in a mouse NF2 model supports a dominant mode of
action for some NF2 mutant alleles. Recently, a report
by Giovannini et al. (1999) showed thatNF2/ trans-
genic mice expressing an NF2-associated mutant allele,
lacking exons 2 and 3, under control of a Schwann cell-
specific promoter, had a high prevalence of Schwann-
cell–derived tumors and schwannosis. Furthermore, the
tumorigenic activity of theNF2 mutant allele was mod-
ulated by the number of NF2 wild-type alleles in vivo,
giving rise to the possibility that the mutant allele may
act as in a dominant-negative manner (Giovannini et
al. 1999). Providing some results to directly address this
possibility, we observed that in the cell-adhesion assay,
the expression of the Drosophila dominant-negative
mutant DBB had no effect on cell attachment, whereas
expression of the Drosophila gain-of-function mutant
Mer559 in cells led to a significant increase in cell de-
tachment. Our findings suggest that some NF2-associ-
ated missense mutations, which account for 10% of
naturally occurring mutations and a subset of truncating
mutations, may act as dominant gain-of-function al-
leles. It is possible that our findings and the findings in
the mouse and Drosophila models are artifacts of ov-
erexpression of inherently unstable proteins or of the
model system. In support of the stability of the missense
proteins in vivo, the half-life of two missense pro-
teins—L64P and L535P—in stable rat schwannoma cell
lines was highly similar to the half-life of isoform 1
(Gutmann et al. 1998), and a meningioma expressing
only a missense NF2 transcript—C300Y—still pro-
duced full-length protein detectable by western analysis
(Takeshima et al. 1998). For most of the missense alleles
used in this study—D118, N220Y, T352M, and
L535P—the status of the second NF2 allele in the tu-
mors was not reported, and the mutation K79E was
found in a sporadic schwannoma with deletion of the
second NF2 allele (Sainz et al. 1994). Thus, no direct
genetic evidence for dominance of missense alleles in
human tumors is available. However, western analysis
of 22 vestibular schwannoma for merlin expression
found that three tumors (14%) expressed both full-
length merlin and a truncated protein containing the N-
terminal domain of merlin (Harwalkar et al. 1998),
which supports the possibility of a dominant mode of
action for a small fraction of NF2 truncating alleles.
This mode of action could partially explain the con-
flicting finding that complete deletions of the gene are
found in mildly affected patients (Evans et al. 1998;
Zucman-Rossi et al. 1998), whereas it would be pre-
dicted that if merlin acts as a traditional tumor-sup-
pressor gene, complete loss of the entire NF2 gene
would be associated with a more-severe disease course.
Since several recurring mutations have been described
in patients with varying degrees of disease severity, it is
also likely that additional genetic and environmental
factors influence the course of the disease. Further de-
tailed characterization of NF2 alleles and merlin ex-
pression in naturally occurring tumors is necessary to
determine the mechanism by which specific NF2mutant
alleles disrupt merlin tumor-suppressor function.
Acknowledgments
We are grateful to Dr. Nila Patil, for her valuable advice and
technical assistance, and to Chris Carlson, for his generous
gift of human lymphocyte cDNA. This work was supported
by National Institutes of Health training grant (GM07790) to
R.P.S.
Electronic-Database Information
The URL for data in this article is as follows:
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim (for NF2 [MIM 101000] and
ERM [MIM 309845])
References
Algrain M, Turunen O, Vaheri A, Louvard D, Arpin M (1993)
Ezrin contains cytoskeleton and membrane binding domains
accounting for its proposed role as a membrane-cytoskeletal
linker. J Cell Biol 120:129–139
Arakawa H, Hayashi N, Nagase H, Ogawa M, Nakamura Y
(1994) Alternative splicing of the NF2 gene and its mutation
analysis of breast and colorectal cancers. Hum Mol Genet
3:565–568
Bhartur SG, Goldenring JR (1998) Mapping of ezrin dimeri-
zation using yeast two-hybrid screening. Biochem Biophys
Res Commun 243:874–877
Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan
T (1994) Germline mutations in the neurofibromatosis type
2 tumour suppressor gene. Hum Mol Genet 3:813–816
Deguen B, Me´rel P, Goutebroze L, Giovannini M, Reggio H,
Arpin M, Thomas G (1998) Impaired interaction of natu-
rally occurring mutant NF2 protein with actin-based cyto-
skeleton and membrane. Hum Mol Genet 7:217–226
den Bakker MA, Riegman PH, Hekman RA, BoersmaW, Jans-
sen PJ, van der Kwast TH, Zwarthoff EC (1995a) The prod-
uct of the NF2 tumour suppressor gene localizes near the
plasma membrane and is highly expressed in muscle cells.
Oncogene 10:757–763
den Bakker MA, Tascilar M, Riegman PH, Hekman AC,
Boersma W, Janssen PJ, de Jong TA, et al (1995b) Neuro-
fibromatosis type 2 protein co-localizes with elements of the
cytoskeleton. Am J Pathol 147:1339–1349
890 Am. J. Hum. Genet. 66:873–891, 2000
Edwards KA, Montague RA, Shepard S, Edgar BA, Erikson
RL, Kiehart DP (1994) Identification of Drosophila cyto-
skeletal proteins by induction of abnormal cell shape in fis-
sion yeast. Proc Natl Acad Sci USA 91:4589–4593
Evans DG, Bourn D, Wallace A, Ramsden RT, Mitchell JD,
Strachan T (1995) Diagnostic issues in a family with late
onset type 2 neurofibromatosis. J Med Genet 32:470–474
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton
V, Harris R (1992) A clinical study of type 2 neurofibro-
matosis. Q J Med 84:603–618
Evans DG, Trueman L,Wallace A, Collins S, Strachan T (1998)
Genotype/phenotype correlations in type 2 neurofibroma-
tosis (NF2): evidence for more severe disease associated with
truncating mutations. J Med Genet 35:450–455
Fernandez-Valle C, Gwynn L, Wood PM, Carbonetto S, Bunge
MB (1994) Anti-beta 1 integrin antibody inhibits Schwann
cell myelination. J Neurobiol 25:1207–1226
Giancotti FG, Ruoslahti E (1990) Elevated levels of the alpha
5 beta 1 fibronectin receptor suppress the transformed phe-
notype of Chinese hamster ovary cells. Cell 60:849–859
Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, van
der Valk M, Woodruff JM, Goutebroze L, Me´rel P, et al
(1999) Schwann cell hyperplasia and tumors in transgenic
mice expressing a naturally occurring mutant NF2 protein.
Genes Dev 13:978–986
Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R, Hobbs W,
Gusella J, Ramesh V (1996) The merlin tumor suppressor
localizes preferentially in membrane ruffles. Oncogene 13:
1239–1247
Gutmann DH, Geist RT, Xu H, Kim JS, Saporito-Irwin S
(1998) Defects in neurofibromatosis 2 protein function can
arise at multiple levels. Hum Mol Genet 7:335–345
Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K,
Hendrix M (1999) Increased expression of the NF2 tumor
suppressor gene product, merlin, impairs cell motility, ad-
hesion and spreading. Hum Mol Genet 8:267–275
Harwalkar JA, Lee JH, Hughes G, Kinney SE, Golubic M
(1998) Immunoblotting analysis of schwannomin/merlin in
human schwannomas. Am J Otol 19:654–659
Hayashi K, Yonemura S, Matsui T, Tsukita S (1999) Immu-
nofluorescence detection of ezrin/radixin/moesin (ERM)
proteins with their carboxyl-terminal threonine phospho-
rylated in cultured cells and tissues. J Cell Sci 112:
1149–1158
Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki
T, Takai Y, et al (1996) Regulation mechanism of ERM
(ezrin/radixin/moesin) protein/plasma membrane associa-
tion: possible involvement of phosphatidylinositol turnover
and Rho-dependent signaling pathway. J Cell Biol 135:
37–51
Huynh DP, Pulst SM (1996) Neurofibromatosis 2 antisense
oligodeoxynucleotides induce reversible inhibition of
schwannomin synthesis and cell adhesion in STS26T and
T98G cells. Oncogene 13:73–84
Hynes RO (1992) Integrins: versatility, modulation, and sig-
naling in cell adhesion. Cell 69:11–25
Jacoby LB, MacCollin M, Louis DN, Mohney T, Rubio MP,
Pulaski K, Trofatter JA, et al (1994) Exon scanning for mu-
tation of the NF2 gene in schwannomas. Hum Mol Genet
3:413–419
Kaiser-Kupfer MI, Freidlin V, Datiles MB, Edwards PA, Sher-
man JL, Parry D, McCain LM, et al (1989) The association
of posterior capsular lens opacities with bilateral acoustic
neuromas in patients with neurofibromatosis type 2. Arch
Ophthalmol 107:541–544
Koga H, Araki N, Takeshima H, Nishi T, Hirota T, Kimura
Y, Nakao M, et al (1998) Impairment of cell adhesion by
expression of the mutant neurofibromatosis type 2 (NF2)
genes which lack exons in the ERM-homology domain. On-
cogene 17:801–810
Kunkel TA, Roberts JD, Zakour RA (1987) Rapid and effi-
cient site-specific mutagenesis without phenotypic selection.
Methods Enzymol 154:367–382
LaJeunesse DR, McCartney BM, Fehon RG (1998) Structural
analysis of Drosophila merlin reveals functional domains
important for growth control and subcellular localization.
J Cell Biol 141:1589–1599
Lamb RF, Ozanne BW, Roy C, McGarry L, Stipp C, Mangeat
P, Jay DG (1997) Essential functions of ezrin in maintenance
of cell shape and lamellipodial extension in normal and
transformed fibroblasts. Curr Biol 7:682–688
Lennon G, Auffray C, Polymeropoulos M, Soares MB (1996)
The I.M.A.G.E. Consortium: an integrated molecular anal-
ysis of genomes and their expression. Genomics 33:151–152
Lutchman M, Rouleau GA (1995) The neurofibromatosis type
2 gene product, schwannomin, suppresses growth of NIH
3T3 cells. Cancer Res 55:2270–2274
MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh
V, Gusella J (1993) DNA diagnosis of neurofibromatosis 2;
altered coding sequence of the merlin tumor suppressor in
an extended pedigree. JAMA 270:2316–2320 (erratum:
JAMA 272:1104 [1994]).
MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP,
Pulaski K, Trofatter JA, et al (1994) Mutational analysis of
patients with neurofibromatosis 2. Am J Hum Genet 55:
314–320
MaedaM,Matsui T, ImamuraM, Tsukita S (1999) Expression
level, subcellular distribution and rho-GDI binding affinity
of merlin in comparison with ezrin/radixin/moesin proteins.
Oncogene 18:4788–4797
Magendantz M, Henry MD, Lander A, Solomon F (1995)
Interdomain interactions of radixin in vitro. J Biol Chem
270:25324–25327
Martin M, Roy C, Montcourrier P, Sahuquet A, Mangeat P
(1997) Three determinants in ezrin are responsible for cell
extension activity. Mol Biol Cell 8:1543–1557
Martuza RL, Eldridge R (1988) Neurofibromatosis 2 (bilateral
acoustic neurofibromatosis). N Engl J Med 318:684–688
Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi
K, Tsukita S (1998) Rho-kinase phosphorylates COOH-ter-
minal threonines of ezrin/radixin/moesin (ERM) proteins
and regulates their head-to-tail association. J Cell Biol 140:
647–657
Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia
C, Solomon F, Gusella J, et al (1998) NHE-RF, a regulatory
cofactor for Na()-H exchange, is a common interactor
for merlin and ERM (MERM) proteins. J Biol Chem 273:
1273–1276
Nakamura F, Amieva MR, Furthmayr H (1995) Phosphory-
lation of threonine 558 in the carboxyl-terminal actin-bind-
Stokowski and Cox: Functional Analysis of NF2 891
ing domain of moesin by thrombin activation of human
platelets. J Biol Chem 270:31377–31385
Nur EKMS, Sizeland A, D’Abaco G, Maruta H (1992) As-
paragine 26, glutamic acid 31, valine 45, and tyrosine 64
of Ras proteins are required for their oncogenicity. J Biol
Chem 267:1415–1418
Obremski VJ, Hall AM, Fernandez-Valle C (1998) Merlin, the
neurofibromatosis type 2 gene product, and beta1 integrin
associate in isolated and differentiating Schwann cells. J
Neurobiol 37:487–501
Reczek D, Berryman M, Bretscher A (1997) Identification of
EBP50: a PDZ-containing phosphoprotein that associates
with members of the ezrin-radixin-moesin family. J Cell Biol
139:169–179
Reczek D, Bretscher A (1998) The carboxyl-terminal region
of EBP50 binds to a site in the amino-terminal domain of
ezrin that is masked in the dormant molecule. J Biol Chem
273:18452–18458
Ritter M, Wo¨ll E, Haller T, Dartsch PC, Zwierzina H, Lang
F (1997) Activation of Na/H()-exchanger by transform-
ing Ha-ras requires stimulated cellular calcium influx and
is associated with rearrangement of the actin cytoskeleton.
Eur J Cell Biol 72:222–228
Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mu¨ller
HW, Hanemann CO (1998) Isolation and characterization
of Schwann cells from neurofibromatosis type 2 patients.
Neurobiol Dis 5:55–64
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J,
Marineau C, Hoang-Xuan K, et al (1993) Alteration in a
new gene encoding a putative membrane-organizing protein
causes neuro-fibromatosis type 2. Nature 363:515–521
Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst
SM (1994) Mutations of the neurofibromatosis type 2 gene
and lack of the gene product in vestibular schwannomas.
Hum Mol Genet 3:885–891
Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson
NG, Tamanoi F, Pulst SM (1998) Neurofibromatosis 2 tum-
our suppressor schwannomin interacts with betaII-spectrin.
Nat Genet 18:354–359
Serrador JM, Alonso-Lebrero JL, del Pozo MA, Furthmayr H,
Schwartz-Albiez R, Calvo J, Lozano F, et al (1997) Moesin
interacts with the cytoplasmic region of intercellular adhe-
sion molecule-3 and is redistributed to the uropod of T lym-
phocytes during cell polarization. J Cell Biol 138:1409–1423
Shaw RJ, McClatchey AI, Jacks T (1998) Regulation of the
neurofibromatosis type 2 tumor suppressor protein, merlin,
by adhesion and growth arrest stimuli. J Biol Chem 273:
7757–7764
Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N,
Ponta H, Herrlich P, et al (1997) Interdomain binding me-
diates tumor growth suppression by the NF2 gene product.
Oncogene 15:2505–2509
Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, Burwick
JA, Beauchamp R, Pinney D, Louis DN, et al (1997) Ex-
pression of NF2-encoded merlin and related ERM family
proteins in the human central nervous system. JNeuropathol
Exp Neurol 56:735–742
Takeshima H, Izawa I, Lee PS, Safdar N, Levin VA, Saya H
(1994) Detection of cellular proteins that interact with
the NF2 tumor suppressor gene product. Oncogene 9:
2135–2144
Takeshima H, Nishi T, Yamamoto K, Kino T, Nakamura H,
Saya H, Kochi M, et al (1998) Loss of merlin-p85 protein
complex in NF2-related tumors. Int J Oncol 12:1073–1078
Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H (1994)
An anti-Ras function of neurofibromatosis type 2 gene prod-
uct (NF2/Merlin). J Biol Chem 269:23387–23390
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao
MP, Parry DM, Eldridge R, et al (1993) A novel moesin-,
ezrin-, radixin-like gene is a candidate for the neurofibro-
matosis 2 tumor suppressor. Cell 75:826
Turunen O, Sainio M, Ja¨a¨skela¨inen J, Carpe´n O, Vaheri A
(1998) Structure-function relationships in the ezrin family
and the effect of tumor-associated point mutations in neu-
rofibromatosis 2 protein. Biochim Biophys Acta 1387:1–16
Turunen O, Wahlstro¨m T, Vaheri A (1994) Ezrin has a COOH-
terminal actin-binding site that is conserved in the ezrin pro-
tein family. J Cell Biol 126:1445–1453
Xu HM, Gutmann DH (1998) Merlin differentially associates
with the microtubule and actin cytoskeleton. J Neurosci Res
51:403–415
Yun CH, Oh S, Zizak M, Steplock D, Tsao S, Tse CM, Wein-
man EJ, et al (1997) cAMP-mediated inhibition of the ep-
ithelial brush border Na/H exchanger, NHE3, requires
an associated regulatory protein. Proc Natl Acad Sci USA
94:3010–3015 (erratum: Proc Natl Acad Sci USA 94:10006
[1997])
Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F,
Bernardi A, Cazes L, et al (1998) NF2 gene in neurofibro-
matosis type 2 patients. Hum Mol Genet 7:2095–2101
